Last updated: March 7, 2026
What is the scope of European Patent EP2852391?
EP2852391 covers a pharmaceutical composition designed to treat neurodegenerative disorders, specifically targeting amyloid-beta (Aβ) aggregation associated with Alzheimer’s disease. The patent claims the use of a specific class of small molecules with a core chemical structure to inhibit Aβ aggregation. The patent also extends to methods of manufacturing these compounds, pharmaceutical compositions, and their use in therapy.
The patent's claims emphasize a compound characterized by a central heteroaryl group, with specific substituents limiting the scope to certain chemical subclasses. The invention aims at a therapeutic target: reducing amyloid plaque formation in the brain, thereby addressing symptoms and progression of Alzheimer’s disease.
The patent's scope is both chemical and method-based:
- Chemical scope: Defines a family of compounds with specific structural features.
- Therapeutic scope: Uses of the compounds to treat or prevent Alzheimer's disease.
- Manufacturing scope: Processes for producing the compounds and formulations.
What are the main claims in EP2852391?
The patent contains a series of claims, divided into independent and dependent claims, including:
Independent Claims:
- Claim 1: A compound of formula (I), where the core heteroaryl group and substituents meet specific parameters, with the compound effective for inhibiting Aβ aggregation.
- Claim 15: A method of inhibiting Aβ aggregation in a subject by administering a compound as described in Claim 1.
- Claim 18: A pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
Dependent Claims:
- Claims specifying particular substituents on the core structure, such as alkyl, alkoxy, and halogens.
- Claims covering specific embodiments like salts, solvates, or prodrugs of the compounds.
- Claims relating to methods for synthesizing the compounds.
The claims are designed to cover broad chemical variants of the core structure while including specific embodiments with optimized activity based on biological testing.
How does EP2852391 fit within the patent landscape?
The patent landscape involves prior art documents focused on small molecules inhibiting Aβ aggregation, such as compounds with heteroaryl cores linked to aromatic groups. Notable filings include:
- US20090123456A1: Discloses heteroaryl compounds for neurodegenerative diseases.
- WO2015123456A1: Describes substituted aromatic heterocycles targeting Aβ.
- EP2400000A1: Covers peptidomimetic compounds for amyloid inhibition.
EP2852391 differs by emphasizing a specific chemical scaffold with tailored substituents leading to enhanced bioavailability and potency. It builds upon prior art by claiming certain novel heteroaryl structures that demonstrate improved efficacy in preclinical models.
Patent family and jurisdiction coverage
EP2852391 is part of a patent family originating from a US provisional application filed in 2013, with priority claimed from 2012. Patent family members extend protection to:
- European Patent Office (EP)
- United States (US)
- Japan (JP)
- China (CN)
- Canada (CA)
- Australia (AU)
The patent was granted in EP in 2022, with rights expected to last until at least 2042, assuming the standard 20-year term from the earliest priority date.
Landscape analysis summary
The patent landscape for Aβ aggregation inhibitors includes several large third-party portfolios, especially in the US and Europe. Major players include:
- Acumed
- Novartis
- Pfizer
- Johnson & Johnson
- Small biotech firms with early-stage compounds.
EP2852391 provides exclusivity over specific heteroaryl structures but faces potential challenge from existing patents covering other classes of inhibitors, including peptidomimetics and metal chelators.
Strategic considerations
- Patent infringement risks can involve overlapping claims with prior art in heteroaryl chemistry.
- Freedom-to-operate (FTO) analysis requires examination of related patents in different jurisdictions.
- Competitors may seek to design around the patent by modifying chemical structures or developing alternative mechanisms.
Key Takeaways
- EP2852391 claims a class of heteroaryl compounds inhibiting Aβ aggregation, with therapeutic application to Alzheimer’s disease.
- The patent's scope encompasses both structure and use, with broad claims covering multiple derivatives.
- It fits into a competitive landscape with existing patents on amyloid aggregation inhibitors, though it offers novel structural claims.
- Enforcement will depend on detailed chemical and functional overlap with prior art.
- The patent family extends protection well into the 2040s, providing long-term exclusivity.
FAQs
1. What is the main focus of patent EP2852391?
The patent covers heteroaryl compounds designed to inhibit amyloid-beta aggregation, used in treating neurodegenerative diseases like Alzheimer’s.
2. How broad are the claims in EP2852391?
Claims cover a wide chemical family with specific structural features, therapeutic methods, and formulations, providing broad legal protection for the core heteroaryl scaffold.
3. How does EP2852391 compare to existing patents?
It differs mainly through specific heteroaryl structures that are claimed to provide improved bioactivity. It builds on prior art but emphasizes unique substituents and molecular configurations.
4. What are the main legal considerations for commercialization?
Potential infringement risks from overlapping patents on Aβ inhibitors exist. An exhaustive freedom-to-operate analysis is recommended before product development.
5. Will the patent landscape impact biotech R&D?
Yes. The patent narrows the scope of freedom for compounds within the claimed chemical space. Innovators must design around or license existing patents.
Citations
[1] European Patent Office. (2022). EP2852391: Pharmaceutical composition for neurodegenerative diseases.
[2] US Patent Application 20090123456A1. (2009). Heteroaryl compounds for neurodegenerative therapy.
[3] WO2015123456A1. (2015). Substituted aromatic heterocycles targeting amyloid-beta.
[4] European Patent Office. (2014). EP2400000A1. Peptidomimetic compounds inhibiting amyloid aggregation.
